{"product_id":"anti-bcma-car-lentivirus-clone-c11d5-3-scfv-cd8-4-1bb-cd3-zeta-bhv18200001","title":"Anti-BCMA CAR Lentivirus (Clone C11D5.3 ScFv-CD8-4-1BB-CD3ζ)","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-license-box{background:#f5f5f5;border:1px solid #ddd;border-radius:4px;padding:12px 16px;font-size:14px;color:#444}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eB-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. To date, the FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eHIV-based · VSV-G-pseudotyped · SIN=Yes\u003c\/span\u003e\u003cp\u003eThe anti-BCMA CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-BCMA (clone C11D5.3) linked to a 2\u003csup\u003end\u003c\/sup\u003e generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. The lentiviruses also transduce a puromycin selection gene.\u003c\/p\u003e\n\u003ch2\u003eTechnical Details\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eVector Type\u003c\/th\u003e\n\u003ctd\u003eHIV-based, VSV-G-pseudotyped lentiviral vector\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePayload \/ Construct\u003c\/th\u003e\n\u003ctd\u003eC11D5.3 ScFv-CD8-4-1BB-CD3ζ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget Antigen \/ Gene\u003c\/th\u003e\n\u003ctd\u003eBCMA (TNFRSF17 \/ CD269)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSignaling \/ Architecture\u003c\/th\u003e\n\u003ctd\u003eCD8 hinge \u0026amp; TM · 4-1BB · CD3ζ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSelection Marker\u003c\/th\u003e\n\u003ctd\u003ePuromycin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReporter\u003c\/th\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eBiosafety Level\u003c\/th\u003e\n\u003ctd\u003eBSL-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSIN Vector\u003c\/th\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eThe lentiviruses were produced from HEK293T cells, concentrated and resuspended in DMEM.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSupplied As\u003c\/th\u003e\n\u003ctd\u003e50 µl of anti-BCMA CAR at a titer ≥ 10\u003csup\u003e8\u003c\/sup\u003e TU\/ml. The titer will vary with each lot; the exact value is provided with each shipment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e−80°C; avoid repeated freeze-thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHazardous Shipping\u003c\/th\u003e\n\u003ctd\u003eUN3373\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eApplications\u003c\/h2\u003e\n\u003cul\u003e\u003cli\u003ePositive control for anti-BCMA CAR evaluation in T cells Transduction optimization studies\u003c\/li\u003e\u003c\/ul\u003e\n\u003ch2\u003eBiosafety \u0026amp; Safety\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Safety Note:\u003c\/strong\u003e Avoid freeze\/thaw cycles.\u003c\/div\u003e\n\u003ch2\u003eLicense \u0026amp; Regulatory\u003c\/h2\u003e\n\u003cdiv class=\"bhp-license-box\"\u003eLicense Disclosure: Visit bpsbioscience.com\/license for the label license and other key information about this product. Troubleshooting Guide: Visit bpsbioscience.com\/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BPS Bioscience","offers":[{"title":"50 uL","offer_id":53322952900973,"sku":"78655","price":1180.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/78655_1.png?v=1778643138","url":"https:\/\/www.ebiohippo.com\/products\/anti-bcma-car-lentivirus-clone-c11d5-3-scfv-cd8-4-1bb-cd3-zeta-bhv18200001","provider":"BioHippo","version":"1.0","type":"link"}